Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-Current Deffered Revenue (2022 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $35.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $35.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $35.0 million for FY2025, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $35.0 million at Actinium Pharmaceuticals, roughly flat from $35.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $35.0 million in Q4 2022, with the low at $35.0 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 4 years is $35.0 million, with a median of $35.0 million recorded in 2022.
  • Peak annual rise in Non-Current Deffered Revenue hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Over 4 years, Non-Current Deffered Revenue stood at $35.0 million in 2022, then changed by 0.0% to $35.0 million in 2023, then changed by 0.0% to $35.0 million in 2024, then changed by 0.0% to $35.0 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $35.0 million, $35.0 million, and $35.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.